Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.
Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.
Enlivex (Nasdaq: ENLV) announced it is a Gold Sponsor of Proof of Talk 2026, held June 2-3, 2026 at the Louvre Palace and Musée des Arts Décoratifs in Paris.
CEO Dr. Oren Hershkovitz will present Enlivex's quality longevity model powered by a prediction markets treasury at a curated institutional investor dinner.
Enlivex (Nasdaq: ENLV) reported extended 3- and 6-month data from its Phase IIa trial of Allocetra in moderate-to-severe knee osteoarthritis. Allocetra showed clinically meaningful, statistically significant pain reduction and functional improvement versus placebo in idiopathic age-related patients ≥60, a group representing over 50% of the KOA market.
The data, highlighting Allocetra’s novel immunomodulating mechanism, were selected for an oral presentation at EULAR 2026 on June 3, 2026. Enlivex said these results supported progression into an ongoing Phase IIb study, where the first US patient was recently dosed.
Enlivex (Nasdaq: ENLV) reported holding 79,568,550,005 RAIN tokens valued at approximately $1.16 billion as of May 27, 2026. The Rain Foundation appointed five crypto and blockchain industry leaders to its advisory board and committed $100 million liquidity to the Rain prediction markets protocol, positioning it as the third-largest prediction market protocol by TVL. Rain's open beta has attracted over 29,000 users and burned more than 100 million RAIN tokens, supporting Enlivex’s view of RAIN as a core treasury asset.
Enlivex (Nasdaq: ENLV) reported updated exposure to the Rain prediction markets protocol treasury.
As of May 26, 2026, Enlivex held about 79.6 billion RAIN tokens valued near $919 million and an option on up to 271.4 billion additional tokens, while Rain received a $100 million liquidity commitment that positions it among the top three global prediction markets by TVL.
Enlivex (Nasdaq: ENLV) dosed the first U.S. patient in its global, randomized, double-blind, placebo-controlled Phase 2b trial of Allocetra for moderate-to-severe age-related primary knee osteoarthritis.
The study spans the United States, Denmark and Poland, with endpoints focused on pain, function, quality of life and mobility.
Enlivex (Nasdaq: ENLV) received a Nasdaq notice that its ordinary shares failed to meet the $1.00 minimum bid price for 30 consecutive business days, triggering a compliance period.
Enlivex has 180 days, until November 9, 2026, to regain compliance, with a possible additional 180-day extension.
Enlivex (Nasdaq: ENLV) announced that its treasury token RAIN was listed on the HTX cryptocurrency exchange, effective April 29, 2026. The listing expands global accessibility and secondary liquidity for RAIN and follows the company disclosure of 78.8 billion RAIN tokens valued at $567 million as of April 27, 2026.
HTX serves over 160 countries, ranked among top global exchanges, and reported roughly $3.3 trillion cumulative trading volume in 2025.
Enlivex (Nasdaq: ENLV) reported its total RAIN holdings rose to 78,819,756,062 tokens as of April 27, 2026, with an aggregated value of $567 million. Recent purchases were made via partial exercises of an option to buy up to 272,121,212,121 RAIN tokens at $0.0033 per token.
The option expires Dec. 31, 2027, and the stated exercise price is an approximately 55% discount to RAIN’s April 27, 2026 closing price.
Enlivex (Nasdaq: ENLV) will present Phase IIa 3-month and 6-month clinical data for Allocetra at the OARSI 2026 World Congress (April 23-26, 2026) in West Palm Beach.
Posters report statistically significant, clinically meaningful reductions in pain and improved function versus placebo in idiopathic age-related KOA patients ≥60, plus pharmacological data on Allocetra's immunomodulating mechanism.
Enlivex (Nasdaq: ENLV) announced Danish Medicines Agency (DKMA) approval to enroll patients in Denmark for the global Phase 2b trial of Allocetra in age-related moderate-to-severe knee osteoarthritis.
This follows recent FDA clearance; the randomized, double-blind, placebo-controlled study will enroll patients in the United States, Denmark and Poland and is powered to assess pain, function and quality-of-life at three and six months.